Interventional Study of Vosoritide for the Treatment of Children with Hypochondroplasia
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).